Sucampo Standardizes on Veeva Vault for a Single Source of Truth Enterprise-wide
April 28 2016 - 7:03AM
Business Wire
High-growth biopharmaceutical company sets
content and information management foundation for greater speed,
agility, and compliance throughout the product lifecycle
Veeva Systems (NYSE:VEEV) announced today that Sucampo
Pharmaceuticals (NASDAQ:SCMP), a fast-growing global
biopharmaceutical company, has standardized on the Veeva Vault
platform and suite of applications to provide a unified foundation
for content and information management. Veeva’s solution will help
Sucampo eliminate information and process siloes across functional
teams, regions, and partners, enabling Sucampo to make information
fully accessible and actionable. Veeva Vault allows Sucampo to
increase efficiency and strengthen compliance with a single source
of truth for content plus life sciences-specific solutions that
streamline key processes throughout the product lifecycle.
Sucampo’s move to Veeva Vault is the cornerstone of its
initiative to ensure greater efficiency and leverage valuable
information created at every stage of a product – including
clinical, quality, regulatory, and commercial. “There is a wealth
of insight that can be gleaned when you have end-to-end visibility
spanning the value chain,” explained Michael Gammons, Sucampo’s
chief information officer and vice president of information
technology. “As a rapidly growing company, it’s critical we set a
foundation for future growth by deploying industry-specific
applications that support our most crucial business functions, all
on one common platform. Veeva Vault is the foundation and provides
the process optimization and single source of truth we need for
agility and speed across the product lifecycle.”
Having valuable product information quickly accessible for
future use in all functional areas, plus key process metrics, can
have tremendous impact on the business. For instance, early-stage
analysis of a compound can be critical to compiling submissions
documents for licensing applications years later. With Veeva Vault,
all content and audit trails are in a central system of record,
reducing complexity and cost.
Veeva Vault also aligns with Sucampo’s corporate initiative to
leverage the efficiencies and agility of Veeva’s industry cloud.
“Our IT department is focused on solving business problems, and,
with Veeva Vault, we get a world-class technology foundation plus
tailored content and information management solutions that fit our
business. We don’t have infrastructure to manage or software we
need to customize,” said Gammons. “As important, Veeva provides
frequent enhancements so we’re always working with the latest
innovations instead of waiting years and investing more to
implement an incremental version upgrade.”
Over the coming months, Sucampo will drive an aggressive
implementation plan to rollout key Veeva Vault solutions worldwide
including: Vault eTMF for clinical trial master file management;
Vault QualityDocs for managing quality, manufacturing, and
validation documents; and Vault Submissions, part of the Vault RIM
suite, for regulatory submissions.
In related news today, Veeva introduced new innovative features
in its latest release of Veeva Vault, version 14, to empower life
sciences companies to streamline their business processes across an
increasingly complex ecosystem of internal and external
stakeholders. Read today’s press release about how the newest
release of Veeva Vault is helping to get products to market faster
and more efficiently.
Additional InformationFor more on Veeva Vault, visit:
veeva.com/vaultStay updated on the latest Veeva news on LinkedIn:
linkedin.com/company/veeva-systemsFollow @veevasystems on Twitter:
twitter.com/veevasystemsLike Veeva on Facebook:
facebook.com/veevasystems
About Veeva SystemsVeeva Systems Inc. is a leader in
cloud-based software for the global life sciences industry.
Committed to innovation, product excellence, and customer success,
Veeva has more than 400 customers, ranging from the world's largest
pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in
Europe, Asia, and Latin America. For more information, visit
www.veeva.com.
Forward-looking StatementsThis release contains
forward-looking statements, including the market demand for and
acceptance of Veeva’s products and services, the results from use
of Veeva’s products and services, and general business conditions,
particularly in the life sciences industry. Any forward-looking
statements contained in this press release are based upon Veeva’s
historical performance and its current plans, estimates, and
expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this
press announcement. Subsequent events may cause these expectations
to change, and Veeva disclaims any obligation to update the
forward-looking statements in the future. These forward-looking
statements are subject to known and unknown risks and uncertainties
that may cause actual results to differ materially. Additional
risks and uncertainties that could affect Veeva’s financial results
are included under the captions, “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations,” in the company’s filing on Form 10-K for the period
ended January 31, 2016. This is available on the company’s website
at veeva.com under the Investors section and on the SEC’s website
at sec.gov. Further information on potential risks that could
affect actual results will be included in other filings Veeva makes
with the SEC from time to time.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160428005595/en/
Veeva SystemsLisa Barbadora, 610-420-3413pr@veeva.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Sep 2023 to Sep 2024